Evidence map›Paper›PMID 38012544›Full record

ArticleBMC gastroenterology2023

Macrophage polarization toward M1 phenotype in T cell transfer colitis model.

Shin Ebihara, Toshiki Urashima, Wataru Amano, Hideto Yamamura, Noriko Konishi

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Anti-Inflammatory Effect of 21Food science & nutrition · 2025
    Article
  4. CD126Orphanet journal of rare diseases · 2025
    Article
  5. Article
  6. Frontiers in pharmacology · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Shin EbiharaBiological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco, Inc, 1-1 Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan. shin.ebihara@jt.com.
Toshiki UrashimaBiological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco, Inc, 1-1 Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan.
Wataru AmanoBiological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco, Inc, 1-1 Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan.
Hideto YamamuraBiological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco, Inc, 1-1 Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan.
Noriko KonishiBiological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco, Inc, 1-1 Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan.
Japan Tobacco (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundT cell transfer colitis model is often used to study the CD4

methodsColitis was induced in scid mice via the adaptive transfer of CD4

resultsInfiltration of macrophages into the colon increased with the development of colitis in the T cell transfer colitis model. M1/M2 macrophage markers were observed in this model, as observed in the colon of patients with inflammatory bowel disease (IBD). Moreover, number of M1 macrophages increased, whereas that of M2 macrophages decreased in the colonic LP during colitis development. M1 macrophages were identified as the main source of inflammatory cytokine production, and colitogenic T cells were activated via interactions with these macrophages.

conclusionsOur findings revealed that macrophages polarized toward the M1 phenotype in LP during colitis development in the T cell transfer colitis model. Therefore, the colitis model is suitable for the evaluation of the efficacy of macrophage-targeted drugs in human IBD treatment. Furthermore, this model can be used to elucidate the in vivo functions of macrophages in the colon of patients with IBD.

Indexed as

ColitisInflammatory Bowel DiseasesAnimalsHumansMacrophagesMicePhenotypeT-LymphocytesM1/M2 markersMacrophageT cell transfer colitis model

Identifiers

PMID38012544
PMCPMC10680295
OpenAlexW4389056750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.